In today’s recent session, 824,118 shares of the Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) have been traded, and its beta is 0.55. Most recently the company’s share price was $5.04, and it changed around $0.12 or 0.02% from the last close, which brings the market valuation of the company to $160.23 Million. CNCE at last check was trading at a discount to its 52-week high of $13.5, offering almost -167.86% off that amount. The share price’s 52-week low was $4.59, which indicates that the recent value has risen by an impressive 8.93% since then. We note from Concert Pharmaceuticals, Inc.’s average daily trading volume that its 10-day average is 359.73 Million shares, with the 3-month average coming to 509.61 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Concert Pharmaceuticals, Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.8. If we narrow it down even further, the data shows that none out of 6 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, no body recommended CNCE as a Hold, whereas 6 deemed it a Buy, and no one rated it as Underweight. Concert Pharmaceuticals, Inc. is expected to report earnings per share of -$0.69 for the current quarter.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Trading Information Today

Instantly CNCE has been showing a green trend so far today with a performance of 2.44% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $5.51- on Wednesday, Apr 07 increased the stock’s daily price by 8.35%. The company’s shares are currently down -0.6% year-to-date, but still up 0.0391 over the last five days. On the other hand, Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) is -0.19% down in the 30-day period. We can see from the shorts that 672.93 Million shares have been sold at a short interest cover period of 1.32 day (s).

The consensus price target as assigned by Wall Street analysts is $15, which translates to bears needing to increase their stock price by 197.62% from its current value. Analyst projections state that CNCE is forecast to be at a low of $11 and a high of $22. In order for the stock price to hit the forecast high, the stock would need to surge +336.51% from its current level, while the stock would need to crash 118.25% from its current level to reach the projected low.

Concert Pharmaceuticals, Inc. (CNCE) projections and forecasts

Concert Pharmaceuticals, Inc. share prices are not performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -53.93 percent over the past six months and at a 7.08% annual growth rate that is well below the industry average of 17.2%. Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain +1.4% in revenue this quarter, and will report a decline of -75.6% in the next quarter. The year-over-year growth rate is expected to be -66.2%, down from the previous year.

Consensus estimates provided by 4 financial analysts predict the company will bring in an average of $370Million in revenue for the current quarter. 4 analysts expect Concert Pharmaceuticals, Inc. to make $370Million in revenue for the quarter ending June 01, 2021. The company’s sales for the same quarters a year ago were $7Million and $6.39 Million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 5185.7%. Forecasts for the next quarter put sales growth at -94.2%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -33.3%. Concert Pharmaceuticals, Inc. earnings are expected to increase by 27.2% in 2021, but the outlook is negative 0% per year for the next five years.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)’s Biggest Investors

Upon looking at major shareholders, it appears that insiders hold 10.15% of Concert Pharmaceuticals, Inc. shares, and 74.65% of them are in the hands of institutional investors. The stock currently has a share float of 83.08%. Concert Pharmaceuticals, Inc. stock is held by 141 institutions, with Blackrock Inc. being the largest institutional investor. By Dec 30, 2020, it held 6.85% of the shares, which is about 2.2 Million shares worth $27.86 Million.

Perceptive Advisors Llc, with 6.68% or 2.15 Million shares worth $27.18 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 30, 2020. The former held 754566 shares worth $9.54 Million, making up 2.35% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 707.97 Thousand shares worth around $4.74 Million, which represents about 2.2% of the total shares outstanding.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

LEAVE A REPLY

Please enter your comment!
Please enter your name here